vs
唐纳森（DCI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
唐纳森的季度营收约是Royalty Pharma plc的1.5倍（$935.4M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 12.2%，领先22.3%），Royalty Pharma plc同比增速更快（4.8% vs 3.9%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 3.3%）
唐纳森是全球知名的过滤解决方案提供商，主要生产销售适配工商业、航空航天、化工、新能源（风电）、食品饮料、医药等多领域的过滤产品，其位于明尼苏达州明尼阿波利斯的研发部门也参与多项军事应用相关的国防项目。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
DCI vs RPRX — 直观对比
营收规模更大
DCI
是对方的1.5倍
$622.0M
营收增速更快
RPRX
高出0.9%
3.9%
净利率更高
RPRX
高出22.3%
12.2%
两年增速更快
RPRX
近两年复合增速
3.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $935.4M | $622.0M |
| 净利润 | $113.9M | $214.2M |
| 毛利率 | 35.2% | — |
| 营业利润率 | 16.0% | 62.4% |
| 净利率 | 12.2% | 34.4% |
| 营收同比 | 3.9% | 4.8% |
| 净利润同比 | 15.1% | 2.9% |
| 每股收益（稀释后） | $0.97 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DCIRPRX
| Q4 25 | $935.4M | $622.0M | ||
| Q3 25 | $980.7M | $609.3M | ||
| Q2 25 | $940.1M | $578.7M | ||
| Q1 25 | $870.0M | $568.2M | ||
| Q4 24 | $900.1M | $593.6M | ||
| Q3 24 | $935.4M | $564.7M | ||
| Q2 24 | $927.9M | $537.3M | ||
| Q1 24 | $876.7M | $568.0M |
净利润DCIRPRX
| Q4 25 | $113.9M | $214.2M | ||
| Q3 25 | $114.3M | $288.2M | ||
| Q2 25 | $57.8M | $30.2M | ||
| Q1 25 | $95.9M | $238.3M | ||
| Q4 24 | $99.0M | $208.2M | ||
| Q3 24 | $109.7M | $544.0M | ||
| Q2 24 | $113.5M | $102.0M | ||
| Q1 24 | $98.7M | $4.8M |
毛利率DCIRPRX
| Q4 25 | 35.2% | — | ||
| Q3 25 | 34.5% | — | ||
| Q2 25 | 34.2% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 35.5% | — | ||
| Q3 24 | 35.8% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 35.2% | — |
营业利润率DCIRPRX
| Q4 25 | 16.0% | 62.4% | ||
| Q3 25 | 15.5% | 70.1% | ||
| Q2 25 | 9.3% | 36.3% | ||
| Q1 25 | 14.4% | 94.0% | ||
| Q4 24 | 14.5% | 60.9% | ||
| Q3 24 | 15.6% | — | ||
| Q2 24 | 15.5% | 50.2% | ||
| Q1 24 | 14.8% | -13.0% |
净利率DCIRPRX
| Q4 25 | 12.2% | 34.4% | ||
| Q3 25 | 11.7% | 47.3% | ||
| Q2 25 | 6.1% | 5.2% | ||
| Q1 25 | 11.0% | 41.9% | ||
| Q4 24 | 11.0% | 35.1% | ||
| Q3 24 | 11.7% | 96.3% | ||
| Q2 24 | 12.2% | 19.0% | ||
| Q1 24 | 11.3% | 0.8% |
每股收益（稀释后）DCIRPRX
| Q4 25 | $0.97 | $0.49 | ||
| Q3 25 | $0.97 | $0.67 | ||
| Q2 25 | $0.48 | $0.07 | ||
| Q1 25 | $0.79 | $0.55 | ||
| Q4 24 | $0.81 | $0.46 | ||
| Q3 24 | $0.90 | $1.21 | ||
| Q2 24 | $0.92 | $0.23 | ||
| Q1 24 | $0.81 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $210.7M | $618.7M |
| 总债务越低越好 | $671.5M | $9.0B |
| 股东权益账面价值 | $1.5B | $9.7B |
| 总资产 | $3.0B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.44× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资DCIRPRX
| Q4 25 | $210.7M | $618.7M | ||
| Q3 25 | $180.4M | $938.9M | ||
| Q2 25 | $178.5M | $631.9M | ||
| Q1 25 | $189.1M | $1.1B | ||
| Q4 24 | $221.2M | $929.0M | ||
| Q3 24 | $232.7M | $950.1M | ||
| Q2 24 | $223.7M | $1.8B | ||
| Q1 24 | $193.8M | $843.0M |
总债务DCIRPRX
| Q4 25 | $671.5M | $9.0B | ||
| Q3 25 | $630.4M | $8.9B | ||
| Q2 25 | $638.8M | $8.0B | ||
| Q1 25 | $514.7M | $7.6B | ||
| Q4 24 | $538.6M | $7.6B | ||
| Q3 24 | $483.4M | $7.6B | ||
| Q2 24 | $481.8M | $7.6B | ||
| Q1 24 | $352.0M | $6.1B |
股东权益DCIRPRX
| Q4 25 | $1.5B | $9.7B | ||
| Q3 25 | $1.5B | $9.6B | ||
| Q2 25 | $1.5B | $9.5B | ||
| Q1 25 | $1.5B | $9.8B | ||
| Q4 24 | $1.5B | $10.3B | ||
| Q3 24 | $1.5B | $10.3B | ||
| Q2 24 | $1.5B | $9.8B | ||
| Q1 24 | $1.4B | $9.9B |
总资产DCIRPRX
| Q4 25 | $3.0B | $19.6B | ||
| Q3 25 | $3.0B | $19.3B | ||
| Q2 25 | $3.0B | $18.3B | ||
| Q1 25 | $3.0B | $17.6B | ||
| Q4 24 | $3.0B | $18.2B | ||
| Q3 24 | $2.9B | $18.0B | ||
| Q2 24 | $2.9B | $17.7B | ||
| Q1 24 | $2.8B | $16.1B |
负债/权益比DCIRPRX
| Q4 25 | 0.44× | 0.92× | ||
| Q3 25 | 0.43× | 0.93× | ||
| Q2 25 | 0.44× | 0.84× | ||
| Q1 25 | 0.33× | 0.78× | ||
| Q4 24 | 0.35× | 0.74× | ||
| Q3 24 | 0.32× | 0.74× | ||
| Q2 24 | 0.32× | 0.78× | ||
| Q1 24 | 0.26× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $111.2M | — |
| 自由现金流率自由现金流/营收 | 11.9% | — |
| 资本支出强度资本支出/营收 | 1.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $403.2M | — |
8季度趋势，按日历期对齐
经营现金流DCIRPRX
| Q4 25 | $125.4M | $827.1M | ||
| Q3 25 | $167.8M | $702.6M | ||
| Q2 25 | $87.7M | $364.0M | ||
| Q1 25 | $90.4M | $596.1M | ||
| Q4 24 | $72.9M | $742.5M | ||
| Q3 24 | $126.0M | $703.6M | ||
| Q2 24 | $141.5M | $658.2M | ||
| Q1 24 | $87.0M | $664.6M |
自由现金流DCIRPRX
| Q4 25 | $111.2M | — | ||
| Q3 25 | $147.5M | — | ||
| Q2 25 | $73.0M | — | ||
| Q1 25 | $71.5M | — | ||
| Q4 24 | $47.9M | — | ||
| Q3 24 | $106.2M | — | ||
| Q2 24 | $120.2M | — | ||
| Q1 24 | $65.7M | — |
自由现金流率DCIRPRX
| Q4 25 | 11.9% | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | 7.8% | — | ||
| Q1 25 | 8.2% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | 13.0% | — | ||
| Q1 24 | 7.5% | — |
资本支出强度DCIRPRX
| Q4 25 | 1.5% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.8% | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 2.4% | — |
现金转化率DCIRPRX
| Q4 25 | 1.10× | 3.86× | ||
| Q3 25 | 1.47× | 2.44× | ||
| Q2 25 | 1.52× | 12.06× | ||
| Q1 25 | 0.94× | 2.50× | ||
| Q4 24 | 0.74× | 3.57× | ||
| Q3 24 | 1.15× | 1.29× | ||
| Q2 24 | 1.25× | 6.45× | ||
| Q1 24 | 0.88× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DCI
| Aftermarket Products | $447.1M | 48% |
| Industrial Filtration Solutions Products | $222.6M | 24% |
| Off Road Products | $86.5M | 9% |
| Life Sciences Segment | $80.0M | 9% |
| Other | $39.1M | 4% |
| Aerospace And Defense Products | $37.1M | 4% |
| On Road Products | $23.0M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
